Author: Frenzel, André; Hust, Michael; Schirrmann, Thomas
Title: Expression of Recombinant Antibodies Document date: 2013_7_29
ID: 06o7pa3d_54
Snippet: Much effort has been set into the establishment and development of plants producing antibodies for therapy, but so far none of these products has appeared on the market, despite of the estimated dramatic reduction of production costs (220) . Nevertheless, at least two plant derived antibodies have been used in clinical trials: CaroRX was developed by Planet Biotechnology (Hayward, CA, USA) and is expressed in transgenic tobacco (221). This antibo.....
Document: Much effort has been set into the establishment and development of plants producing antibodies for therapy, but so far none of these products has appeared on the market, despite of the estimated dramatic reduction of production costs (220) . Nevertheless, at least two plant derived antibodies have been used in clinical trials: CaroRX was developed by Planet Biotechnology (Hayward, CA, USA) and is expressed in transgenic tobacco (221). This antibody binds to the streptococcal antigen I/II of S. mutans, the major causative agent of bacterial tooth decay and prevents the attachment of S. mutans to tooth enamel. CaroRX has entered clinical phase II (222, 223) . A second plant-made antiidiotype antibody against non-Hodgkin-lymphoma (NHL) which was successfully tested in clinical phase I study has been mentioned above (191, 224) .
Search related documents:
Co phrase search for related documents- causative agent and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- causative agent and development establishment: 1
- causative agent and production cost: 1, 2
- causative agent and study clinical phase: 1, 2
- causative agent and therapy antibody: 1, 2, 3
- clinical phase and development establishment: 1
- clinical phase and NHL non hodgkin lymphoma: 1
- clinical phase and non hodgkin lymphoma: 1, 2
Co phrase search for related documents, hyperlinks ordered by date